SAGEMCOM
14.9.2023 16:49:27 CEST | Business Wire | Press release
Sagemcom, a world leader in video, audio, and broadband solutions to operators, today announced that its newest version of its ground-breaking Video Soundbox™ is powered by RDK open-source software.
RDK is an open-source software solution, deployed on more than 100 million devices worldwide, that standardizes core functions and telemetry used in broadband, video, and IoT connected devices. Last year, Sagemcom announced that it became a member of the prestigious RDK Technical Advisory Board and its commitment to embed RDK software throughout its full portfolio of broadband CPE devices (PON, FTTH, DOCSIS, DSL and 5G). Sagemcom also is adopting RDK software within video products, including the Video Soundbox—an all-in-one audio/video entertainment hub, embedding premium speakers and woofer, Dolby Atmos and Dolby Vision certified, with powerful, natural and authentic audio fine-tuned by Bang & Olufsen.
“With the home entertainment market constantly evolving, Sagemcom is always looking for ways to bring innovative and high-quality products to its customers in the best ways possible,” said Olivier Taravel, Senior Executive Video President, Audio Video Solutions BU, Sagemcom. “Our commitment to RDK is foundational to our product roadmaps, and we’re excited to offer the Video Soundbox as the latest product available for RDK operators around the world. We’re also confident that the Video Soundbox is a true product differentiator that can help operators increase customer satisfaction with its high NPS and reduce churn.”
“Sagemcom remains at the forefront of product and service modernization for today’s pay TV and broadband service providers,” said Jason Briggs, RDK President and General Manager. “We’re honored to have them as members of our RDK Technical Advisory Board, and we are particularly pleased to see them adopt RDK into a device as innovative as their Video Soundbox.”
Video Soundbox
Whether watching a movie, streaming music, or just enjoying some background sounds, the Video Soundbox delivers an audio experience that can immerse consumers in their favorite content and bring it to life. Video Soundbox is Dolby Atmos and Dolby Vision certified, meaning it can deliver rich, spatialized sound and crystal clear 4K HDR pictures. This makes it the perfect choice for a home cinema setup, as it allows viewers to fully experience the depth and clarity of modern content.
The Video Soundbox also offers far-field voice control and voice assistance services through its embedded microphones. This makes it easy to use and convenient for multi-user and multi-language scenarios. With the Video Soundbox, consumers can change the volume, switch channels, or play their favorite playlist just by speaking a command.
One of the most compelling reasons for operators to consider deploying the Video Soundbox is its high net promoter score (NPS). This metric measures customer satisfaction and loyalty, and the Video Soundbox consistently shows consumers to be extremely satisfied, which makes it a great retention tool for operators.
For more information on Audio Video Solutions: contact-AVS@sagemcom.com
Additional information about RDK is available at www.rdkcentral.com.
About Sagemcom
Thanks to the innovative solutions designed and built by our people, Sagemcom provides access to broadband Internet, entertainment and managed energy supply to the greatest number all over the world.
As a “mission-driven company” since January 2022, Sagemcom makes sure that the design, construction and use of these solutions are sustainable, and fulfil the environmental and societal commitments that are known and shared by all our employees, partners and stakeholders. Sagemcom is the world leader in Broadband products and solutions, and the European leader in smart metering.
www.sagemcom.com // https://www.linkedin.com/company/sagemcom // www.facebook.com/SagemcomOfficial // https://twitter.com/Sagemcom // https://www.instagram.com/sagemcom_inside.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230915547929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom